In its third quarter, Teva booked revenue of $4.48 billion. That was 3% higher year over year, and much of that growth came ...

Richard Francis, Teva Pharmaceuticals CEO, joins CNBC's 'Money Movers' to discuss the company's most recent quarter, what's ...

Teva Pharmaceutical Industries reported on Wednesday a higher-than-expected rise in third-quarter profit, helped by strong ...

Teva Pharmaceuticals USA, based in Parsippany, New Jersey, issued a voluntary recall on Oct. 7 for some of the prazosin ...

The Food and Drug Administration (FDA) just announced that over 580,000 bottles of blood pressure medications made by Teva ...

Nearly 590,000 bottles of blood pressure drugs have been recalled over concerns that they may contain a potentially ...

The FDA says more than 580,000 bottles of a blood pressure medication have been recalled over concerns that it may contain a ...

A pharmaceutical company has initiated a voluntary recall of more than half a million bottles of its blood pressure ...

Even with Inflation Reduction Act (IRA)-related pressure looming for its top product, Teva Pharmaceuticals is continuing to ...

Teva Q3 revenue rose to $4.48 billion, beating estimates, as Austedo and Ajovy boosted growth; 2025 EPS outlook now ...

Teva shares jumped 12% after Q3 earnings beat estimates, driven by strong branded drug sales led by Austedo and solid guidance for 2025.